Bird Rock Bio, Inc. Gains Approval for Use of Generic Drug Name Nimacimab (RYI-018), a Monoclonal Antibody for the Treatment of NASH, Diabetic Nephropathy and Other Diseases

Bird Rock Bio, Inc. Gains Approval for Use of Generic Drug Name Nimacimab (RYI-018), a Monoclonal Antibody for the Treatment of NASH, Diabetic Nephropathy and Other Diseases

SAN DIEGO, September 7, 2018 — Bird Rock Bio, Inc., announced the approved generic name, nimacimab, was adopted effective August 29th, 2018 and will be submitted to the United States Pharmacopial Convention, Inc. for publication in the USP Dictionary of USAN and International Drug Names. The drug was previously referred to as RYI-018.

“Approval of the generic name nimacimab is important to ensure consistency as we continue to develop this lead antibody in a clinical setting,” said Paul Grayson, President, CEO of Bird Rock Bio, Inc.

About Nimacimab

Discovered internally through Bird Rock Bio’s proprietary iCAPS platform, nimacimab is the first and only known negative-allosteric modulating antibody to the CB1 receptor to be in clinical trials. Nimacimab is a multi-modal therapeutic candidate with fibrotic, inflammatory and metabolic mechanisms of action. This provides the opportunity for nimacimab to have significant potential across a broad range of fibrotic and metabolic diseases including large unmet medical conditions such as nonalcoholic steatohepatitis (NASH) and diabetic nephropathy (DKD).

About ICAPS

Bird Rock Bio’s iCAPS platform, the leading GPCR allosteric antibody drug discovery platform, can isolate and present functional GPCRs in the correct confirmation to identify selective monoclonal antibody allosteric modulators. GPCRs are a valuable class of drug targets but have been largely unexplored in antibody discovery because of the difficulty in isolating GPCRs in the correct conformation and functional form.

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091